SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a notable price decline, prompting widespread community debate on whether it signifies a buying opportunity or further downside, particularly amidst trending rumors associating its origins with Jeffrey Epstein.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending after an earnings miss and weak guidance, compounded by a leadership change, triggering a steep sell-off as the community sharply divides between those labeling it 'PainPal' on a path to further declines and others viewing it as an 'oversold' deep value opportunity given its low valuation and share repurchase program.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as Bitcoin's significant price drop pushes the company's vast BTC holdings underwater, fueling intense community debate about the viability of its leveraged Bitcoin strategy, potential dilution, and the financial implications leading up to its earnings report. Investors are sharply divided between those fearing a "death spiral" and others viewing current levels as a "buy the dip" opportunity for a Bitcoin proxy.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as the US House passing a government funding bill prompts debate about a potential "V-shaped" market recovery, though many traders remain cautious, fearing a "bull trap" amidst broader concerns over an "AI bubble" and shifts in tech leadership. The community is actively discussing whether a sustained rebound or further "bloodbath" in tech is imminent, with upcoming AMD earnings also a key focus.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir (PLTR) is surging after reporting "blowout" Q4 earnings and strong 2026 guidance, driven by accelerating U.S. commercial demand and AI adoption. Community discussion highlights both sustained growth potential and concerns over its still-high valuation, especially as it shows relative strength during a generally weak market.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares plunged following cautious 2026 guidance that forecasts a sales and operating profit decline amid U.S. pricing pressure and patent expirations, prompting a simultaneous share repurchase announcement. Despite the negative outlook, the community largely views the sell-off as an overreaction, pointing to surprisingly strong early uptake of the oral Wegovy pill and positive CagriSema trial results as key long-term growth drivers against rising competition.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending amidst a significant stock price decline, which the community largely attributes to aggressive short selling and a broader market rotation out of small-cap AI names. Despite this, many investors are actively dollar-cost averaging and holding, citing strong fundamentals, recent partnerships, and anticipating a major rebound, while others express frustration and question the company's long-term viability.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as its stock experiences significant price volatility, with many in the community attributing recent drops to perceived market manipulation and short-seller pressure. This occurs despite bullish updates from a recent webinar detailing a substantial AI data center pipeline and backlog, coupled with an analyst price target upgrade, fueling a debate between strong fundamentals and persistent market action.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

SNAP is a major talking point amid a significant stock price decline ahead of its earnings report, fueling community debate over CEO leadership and perceived undervaluation, while proposed global age restrictions on social media and the company's AR glasses spin-off add to the trending conversation.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is experiencing a broad market sell-off, driven by escalating geopolitical tensions following a US military action involving an Iranian drone, alongside ongoing concerns about an AI sector valuation correction and a significant crypto market downturn, leading to community discussions of a 'bloodbath' and hopes for a 'V-shaped recovery' at crucial support levels.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MDXG $RCEL $SOLV $VCEL 

I don’t think SOLV.  We just bought restrata… we don’t need RCEL.   Our teams could easily sell it into burn centers though.

$RCEL   

Who is going to acquire $RCEL in late 2026? 

$SOLV $MDXG $VCEL

StockTwits For Android 

AVITA Medical Inc

Solventum Corp

Mimedx Group Inc

Vericel Corp

Jerry Riston

StockTwits for iOS

 

I don’t think SOLV.  We just bought restrata… we don’t need RCEL.   Our teams could easily sell it into burn centers though.

Durect Corp

Ready Capital Corp

Noneya

@bigbulldaddy I know a lot of acera 1099 and distributors.  You think they will get rid of them and bring all sales to legacy direct.

 I know a lot of acera 1099 and distributors.  You think they will get rid of them and bring all sales to legacy direct.

Jennifer Pennington

@jpenn876 

So it won’t happen right now… they will take their time with it.  Probably second half of year sometime.  Ascera reps are very confident they have strong physician relationships but in reality if you hand us those products now we can sell them with more relationships and contacts realistically.  We truly are the top dogs in wound space and every doctor wants us in their roledex when things go sideways.  Their products aren’t complicated and easily can be sold in our bag.  We really need our associate reps back.  They controlled home DME orders which is big money and they will faulter in first half of year after massive restructure they just did.  This will be first restructure that I think outright should fail.  I think we hire associate reps back at a lower wage and strip ascera bare.  That would likely be a win for solventum.

 

So it won’t happen right now… they will take their time with it.  Probably second half of year sometime.  Ascera reps are very confident they have strong physician relationships but in reality if you hand us those products now we can sell them with more relationships and contacts realistically.  We truly are the top dogs in wound space and every doctor wants us in their roledex when things go sideways.  Their products aren’t complicated and easily can be sold in our bag.  We really need our associate reps back.  They controlled home DME orders which is big money and they will faulter in first half of year after massive restructure they just did.  This will be first restructure that I think outright should fail.  I think we hire associate reps back at a lower wage and strip ascera bare.  That would likely be a win for solventum.

@jpenn876 

All of the ascera reps are making more on average than us.  They can just put it in our commission and lose less to sales and marketing costs.  It’s pretty obvious play to me.

 

All of the ascera reps are making more on average than us.  They can just put it in our commission and lose less to sales and marketing costs.  It’s pretty obvious play to me.